000			03159nam a22004335i 4500
999			_c382618 _d382618
001			382618
003			ES-MaUEC
005			20230102121957.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			220514s2022 si | s |||| 0|eng d
020			_a9789811901973
024	7		_a10.1007/978-981-19-0197-3 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC280.B8 _b2022 EB
245	0	0	_aBreast Cancer : _bfrom Bench to Personalized Medicine _cedited by Saima Shakil Malik, Nosheen Masood
250			_a1st edition 2022
264		1	_aSingapore _bSpringer International Publishing _c2022
300			_a1 recurso en línea (XVII, 536 páginas)
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_aarchivo de texto _bPDF
505	0		_aModule 1_Overview of Breast Cancer -- Module 2_Cell and Molecular Biology of Breast Cancer-Diagnosis and Prognosis -- Module 3_Breast Cancer Treatment.
520			_aThis book provides detailed information on the etiology, pathogenesis, diagnosis, prognosis, and treatment strategies for breast cancer. The first section of the book presents epidemiology, risk factors, histopathological, immunohistochemistry, and molecular subtypes of breast cancer based on the receptor status. It also discusses the association of breast cancer with other hormone-sensitive cancers. The second section of the book covers cover BRCA1 and BRCA2-associated breast carcinogenesis, early-stage progression of breast cancer, and noninvasive biomarkers for the early detection of breast cancer. It also discusses the role of epigenetic modifications and non-coding RNAs in breast cancer metastasis and explores these as the biomarkers and therapeutic targets for breast cancer therapy. Further, it discusses the role of fibrinolytic mechanisms and circulating tumor cells in breast cancer diagnosis, prognosis, and treatment. The book also provides an update on oral poly(ADP-ribose) polymerase (PARP) inhibitors to treat breast cancer. Finally, it offers potential new options for personalized therapies for breast cancer patients, including optimizing drug dosage and identifying genetic changes associated with cancer symptom occurrence and severity.
988			_aSpringer_BiomedLife_2022
650		7	_2embne _9182522 _aMamas _xCáncer
700	1		_aShakil Malik, Saima. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aMasood, Nosheen. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
773	0		_tSpringer Nature eBook
776	0	8	_iPrinted edition: _z9789811901966
776	0	8	_iPrinted edition: _z9789811901980
776	0	8	_iPrinted edition: _z9789811901997
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-981-19-0197-3 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b09/2022 _dz _ep _zSI